Thioredoxin redox regulation in p53 activity
Redox regulation is critical for the functioning of a number of transcription factors. The p53 protein has the structural and biochemical properties of a redoxregulated transcription factor, but the role of redox regulation in the control of p53 activity is rather poorly understood. Thioredoxin (Trx) is a small, ubiquitous, multifunctional, stress-inducible protein with a redox-active disulfide/dithiol within its active site sequence. The findings in this study suggest that the interaction between p53, APE/Ref-1 and Trx may actually serve as a critical crossroad between redox sensing (through Trx), BER (through APE/Ref-1), and DNA-damage sensing (through p53). Furthermore, the redox sensitivity of p53 may provide connection between p53 activity and the sensing and repair of DNA damage.
In this issue of Laboratory Investigation, Kawasaki et al 2 studied the roles of Trx in the host defense mechanism against Helicobacter felis infection. They found that Trx suppressed oxidative cytotoxicity and DNA damage, and inhibited neutrophil migration both in vivo and in vitro. Both studies provide insights to oxidative cytotoxicity and its effect in DNA-damage repair and sensing.
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Genetic differences between primary colorectal carcinomas and their metastases
Colorectal carcinoma is one of the most frequent malignancies in the industrialized world, with a relatively high mortality rate mostly due to metastatic spread of the disease. Substantive insights have been made into the multistep molecular pathogenesis that transforms normal colonic epithelium into a primary colorectal carcinoma. However, the genetic mechanisms that enable a primary colorectal carcinoma to transform into a metastatic phenotype have not been as extensively studied.
Comparative genomic hybridization (CGH) is a new and powerful technique that can evaluate the entire tumor genome for chromosomal gains or losses without the need for cell cultures. These chromosomal gains or losses are likely to contain relevant information on the genes that are involved in malignant transformation.
In an attempt to better understand the genetic underpinnings of pulmonary metastases from colorectal carcinoma, Jiang et al 1 used CGH to compare the genetic profiles of 18 paired samples. The techniques involved purifying the paraffin-embedded tumor and reference DNA, which were respectively labeled with Green and Red-dUTP, and combining this with unlabeled human Cot-1 DNA. The resulting probe mixture was denatured, placed onto a metaphase chromosome slide and hybridized for 3 days. The chromosomes were counterstained and the fluorescence signals from 6-10 captured metaphase cells were combined to obtain an average ratio of tumor to normal DNA for each sample. Thresholds above 1.2 or below 0.8 defined gain or loss of genetic material, respectively. The results focused on specific chromosomal losses or gains in 18 primary and metastatic tumors, as well as on the degree of similarity (clonality relationship ¼ CR) between individual primary and metastasis pairs. The aggregated findings revealed that CGH abnormality profiles were similar for the primary tumors and their pulmonary metastases. The pulmonary metastases, however, contained more CGH abnormalities. They further observed that individual primary and metastasis pairs with high degrees of CR carried more 8p loss in the primary tumors and more 4q loss in the metastases compared to the low-CR group. The authors concluded that primary colon cancers with more genomic lesions, especially 8p and 4q losses, were more likely to metastasize.
Using similar methodologies and subject matter, Tanami et al, 2 in this issue of Laboratory Investigation identified gains in DNA copy-number in chromosome 6p in liver metastases as compared to their colorectal primary. Upon further analysis using CGH-array techniques, CCND3 or Cyclin D3 was the only amplified gene identified after screening colorectal cell culture lines. Quantitative RT-PCR and immunohistochemical staining detected significant upregulation of CCND3 in samples of liver metastases. Expression of CCND3 was then found to correlate (negatively) with clinical outcomes of patients with primary non-metastatic colorectal carcinoma.
In summary, using new and powerful techniques such as CGH, these authors were able to screen the entire genome and identify genetic sequences unique to the metastatic phenotype. This approach can serve as a broad platform to further investigate individual genes and proteins that are involved in this important and complex transformation.
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